Hello, everyone, and how are you today? We are doing just fine, thank you, especially now that the short person has left for the local schoolhouse and the official mascots are officially snoozing. All of which is to say that the Pharmalot campus has quieted down just enough for us to focus on the task at hand, which is foraging for items of interest. Of course, a cup or more of stimulation can be useful, as well. Meanwhile, here are some tidbits to help you on your own journey. Hope your day is simply smashing and do keep us in mind when something interesting arises …

Amazon (AMZN) has shelved plans to sell and distribute pharmaceutical products through Amazon Business, its marketplace for business customers, CNBC tells us.The biggest challenges include complexities around selling in bulk to large hospitals and building a logistics network to handle delivery, but Amazon could still get into pharmaceuticals another way because it still has multiple teams working on health care. And it is worth noting that this development does not address the retail pharmacy business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy